ORASURE TECHNOLOGIES INC
No enriched coverage for $OSUR in the last 7 days.
No SEC Form 4 filings for $OSUR in the last 30 days.
See all $OSUR insider activity →OraSure Technologies (OSUR) reported Q2 2026 revenue of $30.6M, up 9.7% sequentially, including $19.4M Diagnostics revenue and $9.9M Sample Management Solutions revenue. GAAP gross margin was 43.5% and GAAP operating income $5.4M. Q3 revenue guidance is $29.5M to $32.5M. Management said FDA clearance for Colli-Pee and EUA for OraQuick Ebola 2.0 were received, while IntelliQ CT/NG submission was withdrawn.
ORASURE TECHNOLOGIES INC (OSUR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 osur-pressreleaseq22026.htm EX-99.1 Document EXHIBIT 99.1 Investor Contact: Media Contact: investorinfo@orasure.com media@orasure.com OraSure Announces Second Quarter 2026 Financial Results BETHLEHEM, PA, August 5, 2026 (GLOBE NEWSWIRE) – OraSure Technologies, Inc. (Nas
OraSure Technologies said the U.S. FDA granted Emergency Use Authorization for its second generation OraQuick Ebola 2.0 Rapid Antigen Test. The single-use test detects four Ebola virus types and can use blood or oral fluids. OraSure cited improved sensitivity, longer shelf life, and automated manufacturing, and plans to ramp production. The DRC and Uganda outbreak has 2,473 cases and 999 deaths, per Congo’s Ministry of Health.
Recent OSUR coverage spans financial news, regulation and earnings.
Earnings plus a key regulatory timeline reset for IntelliQ CT/NG increases execution risk while other diagnostics milestones (Colli-Pee clearance, OraQuick Ebola EUA) support the growth narrative.
The 8-K combines an earnings-style datapoint (Q2 financials, GAAP and non-GAAP profitability improvement) with forward revenue guidance and two FDA regulatory milestones, which can re-rate near-term expectations.
FDA EUA for a next-gen Ebola diagnostic is a direct regulatory milestone that can drive near-term demand and manufacturing ramp expectations.
FDA clearance expands commercialization optionality for OraSure’s at-home STI testing platform and supports the company’s stated return-to-growth narrative.
FDA clearance expands OraSure’s at-home STI sample-collection addressable market and strengthens its role in decentralized molecular testing workflows.
alphai scores every news story that mentions OSUR with an AI model for sentiment and relevance, and aggregates insider trades from ORASURE TECHNOLOGIES INC's SEC EDGAR Form 4 filings. Figures refresh continuously.
OraSure Technologies (OSUR) reported Q2 2026 revenue of $30.6M, up 9.7% sequentially, including $19.4M Diagnostics revenue and $9.9M Sample Management Solutions revenue. GAAP gross margin was 43.5% and GAAP operating income $5.4M. Q3 revenue guidance is $29.5M to $32.5M. Management said FDA clearance for Colli-Pee and EUA for OraQuick Ebola 2.0 were received, while IntelliQ CT/NG submission was withdrawn.
6 min readORASURE TECHNOLOGIES INC (OSUR) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 osur-pressreleaseq22026.htm EX-99.1 Document EXHIBIT 99.1 Investor Contact: Media Contact: investorinfo@orasure.com media@orasure.com OraSure Announces Second Quarter 2026 Financial Results BETHLEHEM, PA, August 5, 2026 (GLOBE NEWSWIRE) – OraSure Technologies, Inc. (Nas
6 min readOraSure Technologies said the U.S. FDA granted Emergency Use Authorization for its second generation OraQuick Ebola 2.0 Rapid Antigen Test. The single-use test detects four Ebola virus types and can use blood or oral fluids. OraSure cited improved sensitivity, longer shelf life, and automated manufacturing, and plans to ramp production. The DRC and Uganda outbreak has 2,473 cases and 999 deaths, per Congo’s Ministry of Health.
3 min readOraSure (NASDAQ: OSUR) said the FDA has cleared its Colli-Pee at-home urine collection kit, made by subsidiary DNA Genotek, for use with Roche molecular diagnostic systems to identify multiple STIs. OraSure called the clearance important for future growth and noted it also filed for a rapid molecular self-test for Chlamydia and gonorrhoeae. Shares were up over 2% to $4.14.
4 min readOraSure Technologies said the FDA cleared its Colli-Pee™•Dx urine collection kit (from subsidiary DNA Genotek) for at-home first-void urine collection for Roche cobas 5800/6800/8800 molecular testing. The kit supports tests for Chlamydia, Gonorrhea, Trichomonas vaginalis, and Mycoplasma genitalium, enabling mail-in workflows and decentralized STI screening.
3 min readPeapod Lane Capital LLC significantly increased its stake in OraSure Technologies, making it their 17th-largest holding. Meanwhile, insider activity shows the CEO and CFO recently purchased shares, indicating confidence in the company. Despite this, OraSure Technologies is currently trading near $3.05 with a "Reduce" analyst consensus and a target price of $3.00, having reported negative EPS and margins last quarter.
4 min readOraSure Technologies' shares jumped by as much as 15% after the Centers for Medicare and Medicaid Services (CMS) proposed covering hepatitis-C tests for select high-risk patients. OraSure develops a rapid diagnostic test for HCV, making this potential policy change significant for the company's future revenue. If adopted, the proposal could boost OraSure's financial performance and encourage more baby boomers to get tested.
4 min readOraSure Technologies is defending its performance and governance against activist investor Altai Capital's challenge, asserting that its shareholder returns have met or exceeded those of its peers. The company highlights its focused growth strategy, new diagnostic products, cost-cutting measures, and a debt-free balance sheet with share repurchases as evidence of its commitment to shareholder value. An analyst has a Hold rating on OSUR stock with a $3.00 price target, while TipRanks' AI Analyst Spark rates OSUR as Neutral due to past financial underperformance balanced by signs of stabilization and a promising product pipeline.
3 min readOraSure Technologies Inc (OSUR) is currently undervalued, with a fair price estimated between $3.45 and $5.32 compared to its current price of $3.00. While its current P/S ratio of 1.48 is considered undervalued relative to its five-year average, it is still 47.52% above the industry average, which the analysis suggests may be unsustainable given robust revenue growth of -28.53%. The article provides various valuation metrics and compares them to historical averages and industry benchmarks.
4 min readAltai Capital Management L.P. significantly increased its stake in OraSure Technologies, Inc. (NASDAQ:OSUR) during the 3rd quarter, now owning 3,748,836 shares worth approximately $12.03 million and constituting 23.6% of its investment portfolio. This makes OraSure Technologies Altai's second-largest position. Despite strong institutional ownership, analysts have a "Reduce" consensus rating with a target price of $3.00, and the stock recently traded at $2.97.
3 min read
